Trial Profile
A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Enobosarm (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms EMERALD
- 24 Sep 2018 Planned number of patients changed from 146 to 147.
- 24 Sep 2018 Planned End Date changed from 30 Nov 2018 to 31 May 2019.
- 30 Jan 2017 New trial record